Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021

INTRODUCTION: Due to concerns over potential interactions between some hepatitis C direct-acting antivirals (DAAs) and opioids, we describe adverse event (AE) reports of concomitant use of opioids and DAAs. METHODS: AEs reported (July 28, 2017–December 31, 2021) with the administration of the DAAs g...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Anthony, Khan, Tipu, Dylla, Douglas E., Marcinak, John, Collins, Michelle, Saget, Brad, Conway, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544489/
https://www.ncbi.nlm.nih.gov/pubmed/37779203
http://dx.doi.org/10.1186/s12954-023-00874-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544489/
https://www.ncbi.nlm.nih.gov/pubmed/37779203
http://dx.doi.org/10.1186/s12954-023-00874-y

Ejemplares similares